MannKind climbs as FDA approves drug-device combo for fluid buildup
MNKD•FDA approves Furoscix ReadyFlow for edema treatment
Shares of drugmaker MannKind MNKD.O rise 6.4% to $4.13 premarket.
The company says the U.S. FDA approved its single-use injection Furoscix ReadyFlow to treat fluid buildup, or edema, in adults with heart failure or chronic kidney disease.
The autoinjector delivers the drug furosemide under the skin, with IV-equivalent exposure, providing symptom relief in an hour or less.
The approval is supported by positive clinical data that shows the drug is moving through the body exactly as intended to safely and effectively do its job, says MannKind.
Up to last close, the stock was down 31.4% year to date.
